Common use of Annual Commercial Plan Clause in Contracts

Annual Commercial Plan. 3.2.1 Within forty-five (45) days after the Effective Date, and before October 1st of each calendar year commencing in the year 2012, Genzyme and Veracyte shall jointly submit a commercial plan for the subsequent calendar year (each, an “Annual Commercial Plan”) to the Steering Committee for approval. The Annual Commercial Plan will specify in reasonable detail all marketing and promotional activities that Genzyme (and, where applicable, Veracyte) will undertake in each Country during the relevant calendar year. The Annual Commercial Plan shall include, without limitation, the following: (a) the minimum number of quarterly and annual Calls to be provided by Genzyme (and, where applicable, Veracyte) in each Country in the Territories; (b) Test positioning, strategy and tactics with supporting advertising and promotional activity to be undertaken; (c) a determination of the Healthcare Professional accounts that are appropriate and are not appropriate for Calls; (d) any training programs to be conducted; (e) medical and education programs to be conducted; (f) professional and trade relations activities; (g) any information to be specifically included in any Genzyme Detail Report (as defined in Section 3.5 hereof); (h) specifications for the development of promotional and training materials (including the specific types of such materials to be developed); (i) projections for rebates and discounts for the Test; (j) such other information relating to the marketing and sales of the Test as deemed advisable by the Steering Committee; (k) the projected budget for all of the activities and materials anticipated under such plan, including without limitation projected gross xxxxxxxx and Net Revenues (in each case for both cytopathology and the molecular testing), projected billing rates by payor, and a breakdown of the projected costs for the activities and materials anticipated under the Annual Commercial Plan; and (l) a three (3) year rolling sales forecast. Neither party shall make any material change in any previously approved Annual Commercial Plan without the prior written approval of the Steering Committee.

Annual Commercial Plan. 3.2.1 Within forty-five (45) days after the Effective Date, and before October Before April 1st of each calendar year commencing in the year 20122015, Genzyme and Veracyte shall jointly submit an initial draft of a commercial plan for the Territories for the subsequent calendar year (each, an “Annual Commercial Plan”) to the Steering Committee for review and comment. Before October 1st of each calendar year commencing in the year 2015, Genzyme and Veracyte shall jointly submit a final draft of the Annual Commercial Plan for the subsequent calendar year to the Steering Committee for approval. Before November 15th of each calendar years commencing in 2015, the Steering Committee shall approve the final Annual Commercial Plan for the subsequent calendar year. Within ninety (90) days after the Effective Date, the Steering Committee shall approve the Annual Commercial Plan for the calendar year commencing on January 1, 2015. 3.2.2 The Annual Commercial Plan will specify in reasonable detail all marketing and promotional activities that Genzyme (and, where applicable, Veracyte) will undertake in each Country during the relevant calendar year. The Annual Commercial Plan shall include, without limitation, the following: (a) the minimum number of quarterly and annual Calls to be provided by Genzyme (and, where applicable, Veracyte) in each Country in the Territories; (b) Test positioning, strategy and tactics with regard to reimbursement efforts and with regard to supporting advertising and promotional activity to be undertaken; (cb) a determination of the Healthcare Professional accounts that are appropriate and are not appropriate for Calls; (dc) any training programs to be conducted; (ed) medical and education programs to be conducted; (fe) professional and trade relations activities; (gf) any information to be specifically included in any Genzyme Detail Report (as defined in Section 3.5 hereof)Report; (hg) specifications for the development of promotional and training materials (including the specific types of such materials to be developed); (ih) projections for rebates and discounts for the Test; (ji) such other information relating to the marketing and sales of the Test as deemed advisable by the Steering Committee; (kj) the projected budget for all of the activities and materials anticipated under such plan, including without limitation projected gross xxxxxxxx and Net Revenues (in each case for both cytopathology and the molecular testing), projected billing rates by payor, and a breakdown of the projected costs for the activities and materials anticipated under the Annual Commercial Plan; and (lk) a three (3) year rolling sales forecast. Neither party shall make any material change in any previously approved Annual Commercial Plan without the prior written approval of the Steering Committee.

Annual Commercial Plan. 3.2.1 Within forty-five (45) days after The Steering Committee has approved the Effective DateAnnual Commercial Plan for the calendar year commencing on January 1, and before October 2015. Before April 1st of each calendar year commencing in the year 20122015, Genzyme and Veracyte shall jointly submit an initial draft of a commercial plan for the subsequent calendar year (each, an “Annual Commercial Plan”) to the Steering Committee for review and comment. Before October 1st of each calendar year commencing in the year 2015, Genzyme and Veracyte shall jointly submit a final draft of the Annual Commercial Plan for the subsequent calendar year to the Steering Committee for approval. Before November 15th of each calendar year commencing in the year 2015, the Steering Committee shall approve the final Annual Commercial Plan for the subsequent calendar year. The Annual Commercial Plan will specify in reasonable detail all marketing and promotional activities that Genzyme (and, where applicable, Veracyte) will undertake in each Country the Territory during the relevant calendar year. The Each Annual Commercial Plan shall must include, without limitation, the following: (a) the minimum number of quarterly and annual Calls to be provided by Genzyme (andand Veracyte, where applicable, Veracyte) in each Country which in the Territoriescase of Genzyme shall not be less than or exceed an average of *** Calls per Territory Sales Force FTE per calendar quarter and *** Calls per Territory Sales Force FTE per calendar year; (b) Test positioning, strategy and tactics with supporting advertising and promotional activity to be undertaken; (c) a determination of the Healthcare Professional accounts that are appropriate and are not appropriate for Calls; (d) any training programs to be conducted; (e) medical and education programs to be conducted; (f) professional and trade relations activities; (g) any information to be specifically included in any Genzyme Detail Report (as defined in Section 3.5 hereof); (h) specifications for the development of promotional and training materials (including the specific types of such materials to be developed); (i) projections for rebates and discounts for the Test; (j) such other information relating to the marketing and sales of the Test as deemed advisable by the Steering Committee; (k) the projected budget for all of the activities and materials anticipated under such plan, including without limitation projected gross xxxxxxxx and Net Revenues (in each case for both cytopathology and the molecular testing), projected billing rates by payor, and a breakdown of the projected costs for the activities and materials anticipated under the Annual Commercial Plan; and (l) a three (3) year rolling sales forecast. Neither party shall make any material change in any previously approved Annual Commercial Plan without the prior written approval of the Steering Committee.